Effect of the co-administration of HCG and GnRH agonist (dual trigger) versus standard HCG trigger on morphokinetic embryo parameters

Oron, Galia; Sapir, Onit; Shufaro, Yoel; Wertheimer, Avital; Ben-Haroush, Avi

doi:10.1016/j.rbmo.2022.05.013

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Lin MH et al proposed the opposite opinion: dual trigger could significantly improve the clinical pregnancy rate and LBR of patients with DOR, possibly because GnRHa given before ovulation could maintain biological activity during the embryo implantation period due to its longer half-life [14]. One study confirmed that injection of GnRHa during the luteal phase can significantly improve the implantation rate and clinical pregnancy rate of patients [26], and these positive effects seem to be closely related to the regulatory effects of GnRHa on endometrial GnRH receptors, endometrial receptivity, endometrial decidualization and trophoblast invasion [26][27][28][29]. However, it is still uncertain whether GnRHa injected at the time of triggering ovulation can still have high biological activity during the luteal phase, and further research is needed to confirm this phenomenon.…”

Section: Discussionmentioning

confidence: 98%

Reproductive outcomes of dual trigger therapy with GnRH agonist and hCG versus hCG trigger in women with diminished ovarian reserve: a retrospective study

Chen,

Zhang,

Chen

et al. 2024

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background Diminished ovarian reserve (DOR) is one of the obstacles affecting the reproductive outcomes of patients receiving assisted reproductive therapy. The purpose of this study was to investigate whether dual trigger, including gonadotropin‐releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG), can improve pregnancy outcomes in patients with DOR undergoing in vitro fertilization (IVF) cycles using mild stimulation protocols. Methods A total of 734 patients with DOR were included in this retrospective study. Patients were divided into a recombinant hCG trigger group and a dual trigger group (hCG combined with GnRHa) according to the different trigger drugs used. The main outcome measures included the number of oocytes retrieved, the fertilization rate, the number of transferable embryos, the implantation rate, the clinical pregnancy rate, the miscarriage rate, the live birth rate (LBR), and the cumulative live birth rate (CLBR). Generalized linear model and logistic regression analyses were performed for confounding factors. Results There were 337 cycles with a single hCG trigger and 397 cycles with dual trigger. The dual trigger group demonstrated significantly higher numbers of retrieved oocytes [3.60 vs. 2.39, adjusted β = 0.538 (0.221–0.855)], fertilized oocytes [2.55 vs. 1.94, adjusted β = 0.277 (0.031–0.523)] and transferable embryos [1.22 vs. 0.95, adjusted β = 0.162 (-0.005–0.329)] than did the hCG trigger group, whereas no significant difference in the fertilization rate was observed between the two groups. Moreover, the embryo transfer cancellation rate (35.5% vs. 43.9%) was obviously lower in the dual trigger group. Among the fresh embryo transfer cycles, the implantation rate, clinical pregnancy rate, miscarriage rate and live birth rate were similar between the two groups. After controlling for potential confounding variables, the trigger method was identified as an independent factor affecting the number of oocytes retrieved but had no significant impact on the CLBR. Conclusions Dual triggering of final oocyte maturation with hCG combined with GnRHa can significantly increase the number of oocytes retrieved in patients with DOR but has no improvement effect on the implantation rate, clinical pregnancy rate or LBR of fresh cycles or on the CLBR.

show abstract